



(51) International Patent Classification:

C07K 16/32 (2006.01) A61P 35/00 (2006.01)
C07K 16/28 (2006.01) G01N 33/68 (2006.01)
A61K 47/68 (2017.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2021/014790

(22) International Filing Date:

22 January 2021 (22.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/964,747 23 January 2020 (23.01.2020) US

(71) Applicant: **BIOATLA, INC.** [US/US]; 10185 Torreyana Road, Suite 100, San Diego, California 92121 (US).

(72) Inventors: **SHORT, Jay M.**; 12985 Via Esperia, Del Mar, California 92014 (US). **FREY, Gerhard**; 13768 Via Cima Bella, San Diego, California 92129 (US). **CHANG, Hwai**

Wen; 1318 Shadow Hills Drive, San Marcos, California 92069 (US).


(74) Agent: **DUNLEAVY, Kevin J.**; MENDELSON DUNLEAVY, P.C., Kevin J. Dunleavy, 1500 John F. Kennedy Blvd., Suite 910, Philadelphia, Pennsylvania 19102 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: CONDITIONALLY ACTIVE ANTI-HER2 ANTIBODIES, ANTIBODY FRAGMENTS THEIR IMMUNOCONJUGATES AND USES THEREOF

FIG. 9C



(57) Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to HER2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to HER2 protein and multi-specific antibodies that bind to HER2 protein and CD3. Pharmaceutical compositions and kits comprising the polypeptides, antibodies and antibody fragments and multi-specific antibodies containing the polypeptides are also provided

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*